Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director · See Remarks | August 03, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 03, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 717,203 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 4,375 · Balance 717,203 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,410 F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 25,410 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,410 F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 124,956 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 124,956 F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 57,358 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 57,358 F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
F4: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F7: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2020 Filed Jan 7, 2021 19:39 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,000 | $30.00 | $90,000.00 |
DisclosureSEC source: 0001567619-21-000711 · doc1.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,928 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 29, 2020 Filed Jan 7, 2021 19:39 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 3,000 | $1.68 | $5,041.80 |
DisclosureSEC source: 0001567619-21-000711 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 22:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 59,481 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-006469 · doc1.xml · derivative · entry 6 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,492 Underlying: Common Stock · 59,481 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. F6 · derivative.exercise_date: The option vests monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 22:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 59,481 | $1.68 | $99,963.77 |
DisclosureSEC source: 0001567619-20-006469 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 02:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $27.61 | $0.00 |
DisclosureSEC source: 0001567619-20-005552 · doc1.xml · derivative · entry 6 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-02-27 F7 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 02:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 29,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005552 · doc1.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,447 F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 29,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries A Preferred Stock · Derivative | 49,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006601 · doc4.xml · derivative · entry 7 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 49,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries A Preferred Stock · Derivative | 99,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006601 · doc4.xml · derivative · entry 6 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 49,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006601 · doc4.xml · nonDerivative · entry 2 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 49,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 99,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006601 · doc4.xml · nonDerivative · entry 1 Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.